Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 May;68(5):589–594. doi: 10.1136/jnnp.68.5.589

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

P Piccini 1, D Brooks 1, K Korpela 1, N Pavese 1, M Karlsson 1, A Gordin 1
PMCID: PMC1736905  PMID: 10766888

Abstract

OBJECTIVES—Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor. It has been shown to improve the bioavailability of plasma levodopa and extend its clinical effect when used as an adjunct to standard levodopa preparations, but there is little experience of the effect of entacapone on controlled release levodopa preparations.
METHODS—A double blind, placebo controlled, single dose, randomised, cross over trial was performed in 14 patients with Parkinson's disease with motor fluctuations to investigate the clinical effect of a single dose of entacapone (200 mg) when administered with either standard levodopa-carbidopa (SinemetTM) or controlled release levodopa-carbidopa preparations (Sinemet CRTM).
RESULTS—When entacapone was administered with standard SinemetTM the duration of the clinical response to standard SinemetTM was longer in comparison with the response after placebo (p=0.02). Moreover, in the same patients, entacapone significantly increased the duration of the clinical response to Sinemet CRTM (p=0.05) without prolonging the latency of response or enhancing dyskinesias.
CONCLUSIONS—These data confirm the clinical efficacy of entacapone-standard SinemetTM combination. They also indicate that adding entacapone to controlled release levodopa preparations might provide a useful treatment option in patients with Parkinson's disease with motor fluctuations. A double blind clinical trial with a chronically administered entacapone-Sinemet CRTM combination is, however, required to verify this viewpoint.



Full Text

The Full Text of this article is available as a PDF (154.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahtila S., Kaakkola S., Gordin A., Korpela K., Heinävaara S., Karlsson M., Wikberg T., Tuomainen P., Männistö P. T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol. 1995 Feb;18(1):46–57. doi: 10.1097/00002826-199502000-00006. [DOI] [PubMed] [Google Scholar]
  2. Brooks D. J., Ibanez V., Sawle G. V., Playford E. D., Quinn N., Mathias C. J., Lees A. J., Marsden C. D., Bannister R., Frackowiak R. S. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992 Feb;31(2):184–192. doi: 10.1002/ana.410310209. [DOI] [PubMed] [Google Scholar]
  3. Cedarbaum J. M., Breck L., Kutt H., McDowell F. H. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology. 1987 Oct;37(10):1607–1612. doi: 10.1212/wnl.37.10.1607-a. [DOI] [PubMed] [Google Scholar]
  4. Esteguy M., Bonnet A. M., Kefalos J., Lhermitte F., Agid Y. Le test à la L-Dopa dans la maladie de Parkinson. Rev Neurol (Paris) 1985;141(5):413–415. [PubMed] [Google Scholar]
  5. Fabbrini G., Juncos J., Mouradian M. M., Serrati C., Chase T. N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol. 1987 Apr;21(4):370–376. doi: 10.1002/ana.410210409. [DOI] [PubMed] [Google Scholar]
  6. Friedhoff A. J., Bonnet K., Tosengarten H. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa. Res Commun Chem Pathol Pharmacol. 1977 Mar;16(3):411–423. [PubMed] [Google Scholar]
  7. Graham J. S., Henderson J. M., Morris J. G., Yiannikas C. A comparison of standard Madopar and controlled release Madopar in Parkinson's disease. Aust N Z J Med. 1991 Feb;21(1):11–15. doi: 10.1111/j.1445-5994.1991.tb02994.x. [DOI] [PubMed] [Google Scholar]
  8. Hardie R. J., Lees A. J., Stern G. M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 1984 Jun;107(Pt 2):487–506. doi: 10.1093/brain/107.2.487. [DOI] [PubMed] [Google Scholar]
  9. Ishikawa T., Dhawan V., Chaly T., Robeson W., Belakhlef A., Mandel F., Dahl R., Margouleff C., Eidelberg D. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab. 1996 Sep;16(5):854–863. doi: 10.1097/00004647-199609000-00010. [DOI] [PubMed] [Google Scholar]
  10. Jorga K., Fotteler B., Schmitt M., Nielsen T., Zürcher G., Aitken J. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol. 1997;38(1):59–67. doi: 10.1159/000112904. [DOI] [PubMed] [Google Scholar]
  11. Kaakkola S., Teräväinen H., Ahtila S., Rita H., Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology. 1994 Jan;44(1):77–80. doi: 10.1212/wnl.44.1.77. [DOI] [PubMed] [Google Scholar]
  12. Kaakkola S., Wurtman R. J. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res. 1992 Aug 7;587(2):241–249. doi: 10.1016/0006-8993(92)91003-w. [DOI] [PubMed] [Google Scholar]
  13. Karlsson M., Wikberg T. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal. 1992 Aug;10(8):593–600. doi: 10.1016/0731-7085(92)80085-2. [DOI] [PubMed] [Google Scholar]
  14. Keränen T., Gordin A., Harjola V. P., Karlsson M., Korpela K., Pentikäinen P. J., Rita H., Seppälä L., Wikberg T. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol. 1993 Apr;16(2):145–156. doi: 10.1097/00002826-199304000-00007. [DOI] [PubMed] [Google Scholar]
  15. Koller W. C., Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology. 1994 Jul;44(7 Suppl 6):S23–S28. [PubMed] [Google Scholar]
  16. LeWitt P. A. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa. Neurology. 1992 Jan;42(1 Suppl 1):29–60. [PubMed] [Google Scholar]
  17. Marion M. H., Stocchi F., Malcolm S. L., Quinn N. P., Jenner P., Marsden C. D. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Eur Neurol. 1987;27 (Suppl 1):54–58. doi: 10.1159/000116193. [DOI] [PubMed] [Google Scholar]
  18. Marsden C. D., Parkes J. D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977 Feb 12;1(8007):345–349. doi: 10.1016/s0140-6736(77)91146-1. [DOI] [PubMed] [Google Scholar]
  19. Merello M., Lees A. J., Webster R., Bovingdon M., Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):186–189. doi: 10.1136/jnnp.57.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Myllylä V. V., Sotaniemi K. A., Illi A., Suominen K., Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol. 1993;45(5):419–423. doi: 10.1007/BF00315512. [DOI] [PubMed] [Google Scholar]
  21. Nissinen E., Lindén I. B., Schultz E., Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):262–266. doi: 10.1007/BF00173538. [DOI] [PubMed] [Google Scholar]
  22. Nutt J. G., Woodward W. R., Beckner R. M., Stone C. K., Berggren K., Carter J. H., Gancher S. T., Hammerstad J. P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994 May;44(5):913–919. doi: 10.1212/wnl.44.5.913. [DOI] [PubMed] [Google Scholar]
  23. Pahwa R., Lyons K., McGuire D., Silverstein P., Zwiebel F., Robischon M., Koller W. C. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord. 1997 Sep;12(5):677–681. doi: 10.1002/mds.870120508. [DOI] [PubMed] [Google Scholar]
  24. Reches A., Wagner H. R., Jackson-Lewis V., Yablonskaya-Alter E., Fahn S. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology. 1984 Sep;34(9):1208–1212. doi: 10.1212/wnl.34.9.1208. [DOI] [PubMed] [Google Scholar]
  25. Rinne U. K., Larsen J. P., Siden A., Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998 Nov;51(5):1309–1314. doi: 10.1212/wnl.51.5.1309. [DOI] [PubMed] [Google Scholar]
  26. Ruottinen H. M., Rinne J. O., Ruotsalainen U. H., Bergman J. R., Oikonen V. J., Haaparanta M. T., Solin O. H., Laihinen A. O., Rinne U. K. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):91–106. doi: 10.1007/BF02251225. [DOI] [PubMed] [Google Scholar]
  27. Ruottinen H. M., Rinne U. K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol. 1996 Aug;19(4):283–296. doi: 10.1097/00002826-199619040-00001. [DOI] [PubMed] [Google Scholar]
  28. Ruottinen H. M., Rinne U. K. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol. 1996 Jun;19(3):222–233. doi: 10.1097/00002826-199619030-00004. [DOI] [PubMed] [Google Scholar]
  29. Ruottinen H. M., Rinne U. K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):36–40. doi: 10.1136/jnnp.60.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sawle G. V., Burn D. J., Morrish P. K., Lammertsma A. A., Snow B. J., Luthra S., Osman S., Brooks D. J. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology. 1994 Jul;44(7):1292–1297. doi: 10.1212/wnl.44.7.1292. [DOI] [PubMed] [Google Scholar]
  31. Turjanski N., Lees A. J., Brooks D. J. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology. 1997 Sep;49(3):717–723. doi: 10.1212/wnl.49.3.717. [DOI] [PubMed] [Google Scholar]
  32. Wikberg T. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal. 1991;9(2):167–176. doi: 10.1016/0731-7085(91)80140-5. [DOI] [PubMed] [Google Scholar]
  33. Yeh K. C., August T. F., Bush D. F., Lasseter K. C., Musson D. G., Schwartz S., Smith M. E., Titus D. C. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology. 1989 Nov;39(11 Suppl 2):25–38. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES